Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial.

Int J Cancer · 2021 · PMC8048941 · PMID 33348420

Europe PMC DOI

hedged sentence

0.1170

closest p · 2.3× alpha

0.1170

boldest claim

The sentences

a nonsignificant trendP = .117not close (p > 0.1)

Stratification of patients below and above the median fraction of newly detected expanded clones to all expanded clones revealed a nonsignificant trend for patients with higher levels of clonal expansion to have longer OS (HR = 0.57, P = .117, Figure 4G ).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.